BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 1593220)

  • 1. The interactions of penicillamine with copper in vivo and the effect on hepatic metallothionein levels and copper/zinc distribution: the implications for Wilson's disease and arthritis therapy.
    McQuaid A; Lamand M; Mason J
    J Lab Clin Med; 1992 Jun; 119(6):744-50. PubMed ID: 1593220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the effects of penicillamine, trientine, and trithiomolybdate on [35S]-labeled metallothionein in vitro; implications for Wilson's disease therapy.
    McQuaid A; Mason J
    J Inorg Biochem; 1991 Feb; 41(2):87-92. PubMed ID: 2033396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients.
    Sturniolo GC; Mestriner C; Irato P; Albergoni V; Longo G; D'Incà R
    Am J Gastroenterol; 1999 Feb; 94(2):334-8. PubMed ID: 10022625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradigm shift in treatment of Wilson's disease: zinc therapy now treatment of choice.
    Hoogenraad TU
    Brain Dev; 2006 Apr; 28(3):141-6. PubMed ID: 16466879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of cadmium on zinc and copper in liver and in metallothionein.
    Saito S
    Res Commun Mol Pathol Pharmacol; 1996 Dec; 94(3):265-70. PubMed ID: 9029673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Wilson's disease with zinc: III. Prevention of reaccumulation of hepatic copper.
    Brewer GJ; Hill GM; Dick RD; Nostrant TT; Sams JS; Wells JJ; Prasad AS
    J Lab Clin Med; 1987 May; 109(5):526-31. PubMed ID: 3572199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic copper and metallothionein distribution in Wilson's disease (hepatolenticular degeneration).
    Nartey NO; Frei JV; Cherian MG
    Lab Invest; 1987 Oct; 57(4):397-401. PubMed ID: 3312808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Wilson's disease with zinc. VII. Protection of the liver from copper toxicity by zinc-induced metallothionein in a rat model.
    Lee DY; Brewer GJ; Wang YX
    J Lab Clin Med; 1989 Dec; 114(6):639-45. PubMed ID: 2592854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction.
    Yuzbasiyan-Gurkan V; Grider A; Nostrant T; Cousins RJ; Brewer GJ
    J Lab Clin Med; 1992 Sep; 120(3):380-6. PubMed ID: 1517684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Wilson's disease with zinc. XIII: Therapy with zinc in presymptomatic patients from the time of diagnosis.
    Brewer GJ; Dick RD; Yuzbasiyan-Gurkan V; Johnson V; Wang Y
    J Lab Clin Med; 1994 Jun; 123(6):849-58. PubMed ID: 8201263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of long term treatment with penicillamine on the copper content in the liver in patients with Wilson's disease.
    Marecek Z; Heyrovský A; Volek V
    Acta Hepatogastroenterol (Stuttg); 1975 Oct; 22(5):292-6. PubMed ID: 1199668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of copper on zinc in liver and in metallothionein.
    Saito S
    Res Commun Mol Pathol Pharmacol; 1996 Dec; 94(3):259-64. PubMed ID: 9029672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of treatment of Wilson's disease--own observations.
    Jabłońska-Kaszewska I; Drobińska-Jurowiecka A; Dabrowska E; Trocha H
    Med Sci Monit; 2003 Aug; 9 Suppl 3():9-14. PubMed ID: 15156603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical recommendations and new therapies for Wilson's disease.
    Brewer GJ
    Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Wilson's disease with zinc. VI. Initial treatment studies.
    Brewer GJ; Yuzbasiyan-Gurkan V; Lee DY; Appelman H
    J Lab Clin Med; 1989 Dec; 114(6):633-8. PubMed ID: 2592853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pathogenesis and treatment of Wilson's disease].
    Nagy J; Vincze Z; Folhoffer A; Horváth A; Csák T; Zelkó R
    Acta Pharm Hung; 2003; 73(4):237-41. PubMed ID: 15279036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oral zinc in Wilson disease--an alternative to D-penicillamine].
    Ramadori G; Keidl E; Hütteroth T; Dormeyer HH; Manns M; Meyer zum Büschenfelde KH
    Z Gastroenterol; 1985 Jan; 23(1):25-9. PubMed ID: 4060799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zinc treatment prevents lipid peroxidation and increases glutathione availability in Wilson's disease.
    Farinati F; Cardin R; D'inca R; Naccarato R; Sturniolo GC
    J Lab Clin Med; 2003 Jun; 141(6):372-7. PubMed ID: 12819634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Liver copper determination in long-term treatment of Wilson's disease with D-penicillamine].
    Lange J; Brandt G
    Med Welt; 1981 Jan; 32(3):109-10. PubMed ID: 7207132
    [No Abstract]   [Full Text] [Related]  

  • 20. [The onset of psychiatric disorders and Wilson's disease].
    Benhamla T; Tirouche YD; Abaoub-Germain A; Theodore F
    Encephale; 2007 Dec; 33(6):924-32. PubMed ID: 18789784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.